Lenalidomid Zentiva

Lenalidomide, the active ingredient in Lenalidomid Zentiva, is an immunomodulatory agent presented as an oral tablet for oral use. It is indicated for the treatment of multiple myeloma, myelodysplastic syndromes with del(5q), and mantle cell lymphoma in adult patients who have relapsed or refractory disease.

GNH USA supplies Lenalidomid Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance and timely delivery to meet clinical demand.

Lenalidomide is used in hematologic malignancies and related myelodysplastic conditions. - Multiple myeloma: reduces disease progression, prolongs overall survival, and may improve response rates in adult patients. - Myelodysplastic syndromes with del(5q): induces transfusion independence, promotes cytogenetic remission, and can improve hematologic parameters. - Mantle cell lymphoma: provides disease control, can achieve partial responses, and is used in relapsed or refractory settings.

Lenalidomide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Neutropenia: reduced neutrophil count increasing infection risk. - Thrombocytopenia: low platelet levels that may cause bleeding. - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may lead to dehydration. - Rash: skin irritation or erythema. - Constipation: difficulty passing stool.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Secondary primary malignancies: emergence of new cancers. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatotoxicity: elevated liver enzymes or liver injury.

Before initiating Lenalidomid Zentiva, clinicians should consider several precautionary measures to ensure safe use. - Pregnancy risk: contraindicated in pregnancy (Category X); effective contraception required. - Thromboembolic risk: assess for clotting disorders and consider prophylactic anticoagulation. - Renal impairment: adjust monitoring in patients with reduced kidney function. - Hepatic impairment: evaluate liver function before and during therapy. - Infection monitoring: watch for signs of infection due to neutropenia. - Store below 25°C: keep in the original packaging, protect from moisture and light.

Lenalidomid Zentiva can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may reduce lenalidomide exposure. - Anticoagulants (warfarin, DOACs): increased risk of bleeding. - Immunosuppressants (e.g., cyclosporine): heightened hematologic toxicity.

Moderate Interactions (Monitor Closely): - P-glycoprotein substrates (e.g., digoxin): may alter plasma levels. - Vaccines: live attenuated vaccines may be less effective. - Hormonal contraceptives: reduced effectiveness, consider additional methods.